Skip to main content
Alkermes plc. logo

Alkermes plc. — Investor Relations & Filings

Ticker · ALKS ISIN · IE00B56GVS15 US Manufacturing
Filings indexed 1,802 across all filing types
Latest filing 2026-05-01 Regulatory Filings
Country US United States of America
Listing US ALKS

About Alkermes plc.

https://www.alkermes.com/

Alkermes plc is a global biopharmaceutical company that develops and commercializes medicines for diseases of the central nervous system (CNS). The company's research and development efforts focus on complex psychiatric and neurological disorders. Its portfolio includes treatments for conditions such as schizophrenia, bipolar I disorder, alcohol dependence, and opioid dependence. Alkermes' clinical-stage pipeline features investigational therapies, including orexin 2 receptor agonists for sleep disorders like narcolepsy and idiopathic hypersomnia. The company's commercialized products include olanzapine and samidorphan, an oral atypical antipsychotic drug for adults with schizophrenia or bipolar I disorder.

Recent filings

Filing Released Lang Actions
8-K/A - Alkermes plc. (0001520262) (Filer)
Regulatory Filings
2026-05-01 English
ARS - Alkermes plc. (0001520262) (Filer)
Annual Report
2026-04-06 English
DEF 14A - Alkermes plc. (0001520262) (Filer)
Proxy Solicitation & Information Statement
2026-04-06 English
PRE 14A - Alkermes plc. (0001520262) (Filer)
Regulatory Filings
2026-03-27 English
SCHEDULE 13G/A - Alkermes plc. (0001520262) (Subject)
Major Shareholding Notification
2026-03-26 English
4 - ALKERMES PLC. (0001520262) (Filer)
Director's Dealing
2026-02-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.